196 related articles for article (PubMed ID: 11729245)
1. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010.
Xue JL; Ma JZ; Louis TA; Collins AJ
J Am Soc Nephrol; 2001 Dec; 12(12):2753-2758. PubMed ID: 11729245
[TBL] [Abstract][Full Text] [Related]
2. Forecast of the incidence, prevalence and burden of end-stage renal disease in Nanjing, China to the Year 2025.
Sun L; Zou LX; Han YC; Huang HM; Tan ZM; Gao M; Ma KL; Liu H; Liu BC
BMC Nephrol; 2016 Jun; 17(1):60. PubMed ID: 27295981
[TBL] [Abstract][Full Text] [Related]
3. Health care policies/economics of the geriatric renal population.
Eggers PW
Am J Kidney Dis; 1990 Oct; 16(4):384-91. PubMed ID: 2121023
[TBL] [Abstract][Full Text] [Related]
4. Current status of end-stage renal disease care in South Asia.
Jha V
Ethn Dis; 2009; 19(1 Suppl 1):S1-27-32. PubMed ID: 19484871
[TBL] [Abstract][Full Text] [Related]
5. Medicare end stage renal disease population, 1982-87.
Breidenbaugh MZ; Sarsitis IM; Milam RA
Health Care Financ Rev; 1990; 12(1):101-4. PubMed ID: 10113457
[TBL] [Abstract][Full Text] [Related]
6. End-stage renal disease in Canada: prevalence projections to 2005.
Schaubel DE; Morrison HI; Desmeules M; Parsons DA; Fenton SS
CMAJ; 1999 Jun; 160(11):1557-63. PubMed ID: 10373996
[TBL] [Abstract][Full Text] [Related]
7. A quarter century of medicare expenditures for ESRD.
Eggers PW
Semin Nephrol; 2000 Nov; 20(6):516-22. PubMed ID: 11111852
[TBL] [Abstract][Full Text] [Related]
8. Projecting prevalence, costs and evaluating simulated interventions for diabetic end stage renal disease in a Canadian population of aboriginal and non-aboriginal people: an agent based approach.
Gao A; Osgood ND; Jiang Y; Dyck RF
BMC Nephrol; 2017 Sep; 18(1):283. PubMed ID: 28870154
[TBL] [Abstract][Full Text] [Related]
9. The dilemmas of patient treatment for end-stage renal disease.
Schmidt RW; Blumenkrantz M; Wiegmann TB
Am J Kidney Dis; 1983 Jul; 3(1):37-47. PubMed ID: 6346866
[TBL] [Abstract][Full Text] [Related]
10. End-stage renal disease in the United States: an update from the United States Renal Data System.
Foley RN; Collins AJ
J Am Soc Nephrol; 2007 Oct; 18(10):2644-8. PubMed ID: 17656472
[TBL] [Abstract][Full Text] [Related]
11. Association of the Comprehensive End-Stage Renal Disease Care Model With Medicare Payments and Quality of Care for Beneficiaries With End-Stage Renal Disease.
Marrufo G; Colligan EM; Negrusa B; Ullman D; Messana J; Shah A; Duvall T; Hirth RA
JAMA Intern Med; 2020 Jun; 180(6):852-860. PubMed ID: 32227133
[TBL] [Abstract][Full Text] [Related]
12. Renal replacement therapy in the United States: data from the United States Renal Data System.
Agodoa LY; Eggers PW
Am J Kidney Dis; 1995 Jan; 25(1):119-33. PubMed ID: 7810518
[TBL] [Abstract][Full Text] [Related]
13. Financing of end-stage renal disease care: past, present, and future.
Farley DO
Adv Ren Replace Ther; 1994 Apr; 1(1):24-31. PubMed ID: 7641085
[TBL] [Abstract][Full Text] [Related]
14. Projecting the United States ESRD population: issues regarding treatment of patients with ESRD.
Szczech LA; Lazar IL
Kidney Int Suppl; 2004 Sep; (90):S3-7. PubMed ID: 15296500
[TBL] [Abstract][Full Text] [Related]
15. End-stage renal disease: magnitude of the problem, prognosis of future trends and possible solutions.
Port FK
Kidney Int Suppl; 1995 Aug; 50():S3-6. PubMed ID: 8544432
[TBL] [Abstract][Full Text] [Related]
16. The organization and financing of kidney dialysis and transplant care in the United States of America.
Hirth RA
Int J Health Care Finance Econ; 2007 Dec; 7(4):301-18. PubMed ID: 17602296
[TBL] [Abstract][Full Text] [Related]
17. Extent and sources of geographic variation in Medicare end-stage renal disease expenditures.
Hirth RA; Tedeschi PJ; Wheeler JR
Am J Kidney Dis; 2001 Oct; 38(4):824-31. PubMed ID: 11576886
[TBL] [Abstract][Full Text] [Related]
18. Excluded from universal coverage: ESRD patients not covered by Medicare.
Thamer M; Ray NF; Richard C; Greer JW; Pearson BC; Cotter DJ
Health Care Financ Rev; 1995; 17(2):123-46. PubMed ID: 10157372
[TBL] [Abstract][Full Text] [Related]
19. Sociodemographic and geographic predictors of quality of care in United States patients with end-stage renal disease due to lupus nephritis.
Plantinga LC; Drenkard C; Patzer RE; Klein M; Kramer MR; Pastan S; Lim SS; McClellan WM
Arthritis Rheumatol; 2015 Mar; 67(3):761-72. PubMed ID: 25692867
[TBL] [Abstract][Full Text] [Related]
20. Prediction of end-stage renal disease patient population in Japan by system dynamics model.
Motohashi Y; Nishi S
Int J Epidemiol; 1991 Dec; 20(4):1032-6. PubMed ID: 1800400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
